Gary D. Steinberg, MD

Articles

Dr. Steinberg on the Standard of Care in Non-Muscle Invasive Bladder Cancer

January 24th 2019

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the standard of care in patients with non-muscle invasive bladder cancer (NMIBC).

Dr. Steinberg on Treatment Approaches in Non-Muscle Invasive Bladder Cancer

October 9th 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses treatment approaches in non-muscle invasive bladder cancer (NMIBC).

Dr. Steinberg on the Management of Prostate Cancer

October 2nd 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the management of patients with prostate cancer.

Dr. Steinberg on BCG Progression in Non-Muscle Invasive Bladder Cancer

September 22nd 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses bacillus Calmette-Guérin (BCG) progression in non-muscle invasive bladder cancer (NMIBC).

Dr. Steinberg on Trial of HS-410 Vaccine in Bladder Cancer

February 18th 2017

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).

Dr. Gary Steinberg on New AUA Guidelines for Bladder Cancer

June 28th 2016

Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer

May 19th 2016

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.